CD8A and non-small cell lung carcinoma: Based on these data, authors did a retrospective analysis of pretreatment biopsies of 21 stage IV NSCLC patients undergoing anti-PD-1 therapy, revealing a clear correlation between the presence of these PD-1+ high CD8+ T cells and the response to treatment and also with the overall survival (OS) (HR 0.16, p < 0.05) [15,16,17].